Trial reportThe American journal of tropical medicine and hygiene2013
Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.
Trial report in The American journal of tropical medicine and hygiene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Interventions for American cutaneous and mucocutaneous leishmaniasis.The Cochrane database of systematic reviews · 2020Pooled it
- Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.PLoS neglected tropical diseases · 2014Pooled it
- Topical paromomycin for New World cutaneous leishmaniasis.PLoS neglected tropical diseases · 2019Trial
- Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis.Antimicrobial agents and chemotherapy · 2013Trial
- Cutaneous leishmaniasis: epidemiology, treatment access and translational challenges of topical therapies.Frontiers in microbiology · 2025Review
- Self-application of aminoglycoside-based creams to treat cutaneous leishmaniasis in travelers.PLoS neglected tropical diseases · 2023Article
- In Vivo Safety and Efficacy of Chalcone-Loaded Microparticles with Modified Polymeric Matrix against Cutaneous Leishmaniasis.Pharmaceutics · 2022Article
- Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis-An updated review.Frontiers in bioengineering and biotechnology · 2022Review
- Clinical diversity and treatment results in Tegumentary Leishmaniasis: A European clinical report in 459 patients.PLoS neglected tropical diseases · 2021Observational
- Effectiveness of doxycycline for the treatment of zoonotic cutaneous leishmaniasisParasitology · 2021Article
- Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review.PLoS neglected tropical diseases · 2021Review
- Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.International journal for parasitology. Drugs and drug resistance · 2019Article
- Therapeutic response and safety of the topical, sequential use of antiseptic, keratolytic, and pentamidine creams (3-PACK) on Leishmania (Viannia) braziliensis-infected mice.Memorias do Instituto Oswaldo Cruz · 2019Article
- DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis.Scientific reports · 2016Article
- Annihilation of Leishmania by daylight responsive ZnO nanoparticles: a temporal relationship of reactive oxygen species-induced lipid and protein oxidation.International journal of nanomedicine · 2016Article
- Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.Current infectious disease reports · 2015Article
- An update on pharmacotherapy for leishmaniasis.Expert opinion on pharmacotherapy · 2015Review
- Intrachromosomal amplification, locus deletion and point mutation in the aquaglyceroporin AQP1 gene in antimony resistant Leishmania (Viannia) guyanensis.PLoS neglected tropical diseases · 2015Article
- Drug repurposing for the treatment of staphylococcal infections.Current pharmaceutical design · 2015Review
- In response.The American journal of tropical medicine and hygiene · 2014Article
Corrections and comments
- Commented on by
- Commented on byIn response.2014
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this randomized, double-blinded Phase 2 trial, 30 patients with Leishmania panamensis cutaneous leishmaniasis were randomly allocated (1:1) to receive once daily topical treatment with WR 279,396 (15% paromomycin + 0.5% gentamicin) or Paromomycin Alone (15% paromomycin) for 20 days. The index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone (P = 0.099). When all treated lesions were included, the final cure rate for WR 279,398-treated patients was again 87%, but the final cure rate for Paromomycin Alone-treated patients was 8 of 15 (53.3%; P = 0.046). Both creams were well tolerated with mild application site reactions being the most frequent adverse event. The increased final cure rate in the WR 279,396 group in this small Phase 2 study suggests that the combination product may provide greater clinical benefit than paromomycin monotherapy against L. panamensis cutaneous leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.